In patients with hypertension, a patient activation intervention increased rates of switching to a thiazide, suggesting that such interventions may address medication optimization challenges.
TRIBE-2 by GONO group: A phase III strategy study in the first- and second-line treatment of unresectable metastatic colorectal cancer (mCRC) patients. Background: Regorafenib is an oral multikinase ...
A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers. Background: Patients with advanced colorectal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results